GSK2831781 - Double Blind Phase ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
97潰瘍性大腸炎1

97. 潰瘍性大腸炎


臨床試験数 : 2,630 薬物数 : 1,459 - (DrugBank : 265) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03893565
(ClinicalTrials.gov)
May 6, 201926/3/2019Safety, Tolerability, Efficacy and Dose-response of GSK2831781 in Ulcerative ColitisA Multicentre Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Safety, Tolerability, Efficacy, Dose-response, Pharmacokinetics and Pharmacodynamics of Repeat Dosing of an Anti-LAG3 Cell Depleting Monoclonal Antibody (GSK2831781) in Patients With Active Ulcerative ColitisColitis, UlcerativeDrug: GSK2831781 - Double Blind Phase;Drug: Placebo;Drug: GSK2831781 - Open Label phaseGlaxoSmithKlineNULLTerminated18 YearsN/AAll104Phase 2United States;Bulgaria;Czechia;Estonia;France;India;Japan;Netherlands;Poland;Russian Federation;Serbia;Slovakia;South Africa;Ukraine;United Kingdom;Belgium;Canada;Hungary;Korea, Republic of